Literature DB >> 28249975

Improving the accuracy of synovial fluid analysis in the diagnosis of prosthetic joint infection with simple and inexpensive biomarkers: C-reactive protein and adenosine deaminase.

R Sousa1, P Serrano1, J Gomes Dias2, J C Oliveira1, A Oliveira1.   

Abstract

AIMS: The aims of this study were to increase the diagnostic accuracy of the analysis of synovial fluid in the differentiation of prosthetic joint infection (PJI) by the addition of inexpensive biomarkers such as the levels of C-reactive protein (CRP), adenosine deaminase (ADA), alpha-2-macrogloblulin (α2M) and procalcitonin. PATIENTS AND METHODS: Between January 2013 and December 2015, synovial fluid and removed implants were requested from 143 revision total joint arthroplasties. A total of 55 patients met inclusion criteria of the receipt of sufficient synovial fluid, tissue samples and removed implants for analysis. The diagnosis of PJI followed the definition from a recent International Consensus Meeting to create two groups of patients; septic and aseptic. Using receiver operating characteristic curves we determined the cutoff values and diagnostic accuracy for each marker.
RESULTS: There were 23 PJIs and 32 patients with aseptic loosening. The levels of total leucocyte count, proportion of polymorphonuclear leucocytes (PMNs), CRP, ADA and α2M in the synovial fluid were all significantly higher in those with a PJI than in those with aseptic loosening. The levels of procalcitonin were comparable in the two groups. Cutoff values for the optimal performance in the diagnosis of infection were: total leucocyte count > 1463 cells/μL (sensitivity (Sens) 100%, specificity (Spec) 71.9%, positive predictive value (PPV) 71.9%, negative predictive value (NPV) 100%); proportion of PMNs > 81% (Sens 78.3%, Spec 75.0%, PPV 69.2%, NPV 82.8%); CRP > 6.7mg/L (Sens 78.3%, Spec 93.8%, PPV 90.0%, NPV 85.7%); ADA > 61U/L (Sens 78.3%, Spec 96.9%, PPV 94.7%, NPV 86.1%) and α2M > 958 mg/L (Sens 47.8%, Spec 96.9%, PPV 91.7%, NPV 72.1%). The addition of a raised level of CRP or ADA to the total leukocyte count increased the specificity: total leukocyte count > 1463 cells/μL and CRP > 6.7mg/L (Sens 78.3%, Spec 100%, PPV 100%, NPV 86.5%) or with ADA > 61U/L (Sens 78.3%, Spec 96.9%, PPV 94.7%, NPV 86.1%).
CONCLUSION: The total leucocyte count in the synovial fluid offers great negative predictive value in the diagnosis of PJI and the addition of more specific markers such as CRP and ADA improves the positive predictive value. Thus the addition of simple and inexpensive markers to the measurement of the leucocyte count in the synovial fluid may reduce the number of equivocal results which demand more expensive investigation. Cite this article: Bone Joint J 2017;99-B:351-7. ©2017 The British Editorial Society of Bone & Joint Surgery.

Entities:  

Keywords:  Adenosine deaminase; Biomarker; C-reactive protein; Leukocyte count; Prosthetic joint infections; Synovial fluid

Mesh:

Substances:

Year:  2017        PMID: 28249975     DOI: 10.1302/0301-620X.99B3.BJJ-2016-0684.R1

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  12 in total

1.  In Reply.

Authors:  Christina Otto-Lambertz
Journal:  Dtsch Arztebl Int       Date:  2017-10-27       Impact factor: 5.594

2.  Absence of signature inflammatory markers in synovial fluid for total knee arthroplasties revised for arthrofibrosis.

Authors:  Christopher G Salib; Nicolas Reina; Andre J van Wijnen; Arlen D Hanssen; Daniel J Berry; Matthew P Abdel
Journal:  Orthop Traumatol Surg Res       Date:  2021-02-24       Impact factor: 2.256

3.  The EBJIS definition of periprosthetic joint infection.

Authors:  Martin McNally; Ricardo Sousa; Marjan Wouthuyzen-Bakker; Antonia F Chen; Alex Soriano; H Charles Vogely; Martin Clauss; Carlos A Higuera; Rihard Trebše
Journal:  Bone Joint J       Date:  2021-01       Impact factor: 5.082

4.  Preliminary evaluation of a rapid lateral flow calprotectin test for the diagnosis of prosthetic joint infection.

Authors:  Alexander J Trotter; Rachael Dean; Celia E Whitehouse; Jarle Mikalsen; Claire Hill; Roxanne Brunton-Sim; Gemma L Kay; Majeed Shakokani; Alexander Z E Durst; John Wain; Iain McNamara; Justin O'Grady
Journal:  Bone Joint Res       Date:  2020-06-08       Impact factor: 5.853

5.  Bacterial Extracellular DNA Production Is Associated with Outcome of Prosthetic Joint Infections.

Authors:  Beata Zatorska; Carla Renata Arciola; Nicolas Haffner; Luigi Segagni Lusignani; Elisabeth Presterl; Magda Diab-Elschahawi
Journal:  Biomed Res Int       Date:  2018-10-22       Impact factor: 3.411

6.  The importance of appropriate diagnostics in prosthetic joint infection: letter to the editor of BMC musculoskeletal disorders.

Authors:  Martin McNally; Marjan Wouthuyzen-Bakker; Ricardo Sousa; Bridget Atkins; Alex Soriano
Journal:  BMC Musculoskelet Disord       Date:  2021-03-08       Impact factor: 2.362

Review 7.  Optimal microbiological sampling for the diagnosis of osteoarticular infection.

Authors:  Ricardo Sousa; André Carvalho; Ana Cláudia Santos; Miguel Araújo Abreu
Journal:  EFORT Open Rev       Date:  2021-06-28

8.  Fibrinogen - A Practical and Cost Efficient Biomarker for Detecting Periprosthetic Joint Infection.

Authors:  S M Klim; F Amerstorfer; G Gruber; G A Bernhardt; R Radl; L Leitner; A Leithner; M Glehr
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

9.  Selection and Investigation of a Primate Model of Spontaneous Degenerative Knee Osteoarthritis, the Cynomolgus Monkey (Macaca Fascicularis).

Authors:  Gang Liu; Lei Zhang; Xin Zhou; Bao L Zhang; Guang X Guo; Ping Xu; Guo Y Wang; Shi J Fu
Journal:  Med Sci Monit       Date:  2018-07-01

10.  Alpha defensin, leukocyte esterase, C-reactive protein, and leukocyte count in synovial fluid for pre-operative diagnosis of periprosthetic infection.

Authors:  Elena De Vecchi; Carlo Luca Romanò; Roberta De Grandi; Laura Cappelletti; Francesca Villa; Lorenzo Drago
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Mar-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.